Earnings Releases·Nov 5, 2026, 7:32 AM ET

Collegium Pharmaceutical — Q3 2026 Earnings Summary

Record quarterly net revenues reached $216.3 million (up 3% year-over-year), driven by a 24% increase in JORNAY PM revenue to $51.9 million, while the Pain Portfolio declined 18% to $138.0 million.
GAAP net income decreased to $21.8 million ($0.60 diluted EPS) from $31.5 million ($0.84 diluted EPS) in the prior year period, and adjusted EBITDA fell 9% year-over-year to $121.6 million.
Management reaffirmed full-year 2026 guidance for Product Revenues ($825–$855 million) and Adjusted EBITDA ($445–$470 million), while announcing a $50 million accelerated share repurchase program expected to settle in Q4 2026.
AZSTARYS generated $26.5 million in its first full quarter under Collegium ownership, reversing prior annual prescription declines, and the company ended the quarter with $144.8 million in cash and marketable securities.